GleamWall
中文EN

SLXN Silexion Therapeutics Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2022416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-43.1%
TTM EPS YoY-211.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-266.0%
ROA-143.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets56.5%
Debt / equity0.00x
Current ratio1.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$7.14M$5.82M
SG&A expense$4.49M$6.76M
Operating income-$11.63M-$12.57M
Pretax income-$11.91M-$16.51M
Income tax$3,000$10,000
Net income-$11.91M-$16.52M
EBITDA-$11.62M-$12.55M
EPS (basic)8.96394.94
EPS (diluted)8.96394.94
Weighted avg. shares (diluted)1.33M41,635
Balance sheet
Cash & equivalents$5.99M$1.27M
Current assets$6.64M$2.25M
PP&E, net$25,000$30,000
Total assets$7.21M$2.86M
Current liabilities$2.76M$3.52M
Total liabilities$4.61M$6.85M
Shareholders' equity$2.60M-$3.99M
Shares outstanding13,028123.29M
Cash flow statement
Operating cash flow-$10.82M-$8.40M
Capital expenditure$9,000$22,000
Free cash flow-$10.83M-$8.42M
Investing cash flow-$14,000-$22,000
Financing cash flow$15.64M$5.10M
Depreciation & amortization$14,000$25,000
Stock-based compensation$134,000$5.86M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.